Program
ravulizumab
Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 349 open or running | phase 4since Mar 23, 2020 | Nov 2, 2015 | Jun 25, 2027phase 4 · NCT07308574 |
| Regeneron Pharmaceuticals | 10 open or running | phase 3since Nov 12, 2021 | Nov 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Nov 2, 2015.
- Nov 12, 2021Regeneron Pharmaceuticals's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05131204 · 3 enrolled · United States
- Mar 11, 20224 phase 1 studies in HealthyAstraZeneca · NCT05288829, NCT05288816, NCT05288673 and 1 more
- Apr 20, 2022Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT05346354 · 12 enrolled · United States, Canada, France and more
- May 25, 2022Phase 1 study in HealthyAstraZeneca · NCT05396742 · 49 enrolled · United Kingdom
- Dec 1, 2022Phase 3 study in Myasthenia GravisAstraZeneca · NCT05644561 · 12 enrolled · United States, Italy, Japan and more
- Feb 16, 2023Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT05746559 · 555 enrolled · United States, Argentina, Australia and more
- Feb 26, 2024Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT06291376 · 584 enrolled · United States, Argentina, Australia and more
- Aug 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalAstraZeneca · NCT06578949 · 18 enrolled · China
- Feb 10, 2025Phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798 · 450 planned · United States, Argentina, Australia and more
- Jun 9, 2025Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT07024563 · 36 planned · United States, China, Italy and more
- Oct 3, 2025Phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838 · 75 planned · United States, Germany, Italy and more
- Dec 17, 2025Phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574 · 20 planned · Japan
- Apr 23, 2026Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT07557420 · 19 planned · China
- May 13, 2026Phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784 · 20 planned · China
Ahead
- Jun 25, 2027Primary completion: phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574
- Aug 24, 2027Primary completion: phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784
- Aug 27, 2027Primary completion: phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838
- Nov 30, 2027Primary completion: phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07596784Myasthenia Gravis · China | 3 | Recruiting | AstraZeneca | Aug 24, 2027 | 20 |
| NCT07557420Neuromyelitis Optica · China | 3 | Recruiting | AstraZeneca | Sep 19, 2028 | 19 |
| NCT07308574Atypical Hemolytic Uremic Syndrome · Japan | 4 | Recruiting | AstraZeneca | Jun 25, 2027 | 20 |
| NCT07221838Myasthenia Gravis · United States, Germany, Italy and more | 4 | Recruiting | AstraZeneca | Aug 27, 2027 | 75 |
| NCT07024563Glomerulonephritis, IGA · United States, China, Italy and more | 3 | Recruiting | AstraZeneca | Nov 29, 2028 | 36 |
| NCT06830798Delayed Graft Function · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Nov 30, 2027 | 450 |
| NCT06578949Hemoglobinuria, Paroxysmal · China | 3 | Completed | AstraZeneca | May 15, 2025 | 18 |
| NCT06291376Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Jan 5, 2026 | 584 |
| NCT05746559Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Terminated | AstraZeneca | Oct 7, 2025 | 555 |
| NCT05644561Myasthenia Gravis · United States, Italy, Japan and more | 3 | Active, not recruiting | AstraZeneca | Jul 15, 2026 | 12 |
| NCT05396742Healthy · United Kingdom | 1 | Completed | AstraZeneca | May 21, 2019 | 49 |
| NCT05346354Neuromyelitis Optica · United States, Canada, France and more | 3 | Active, not recruiting | AstraZeneca | Jun 22, 2026 | 12 |
| NCT05288829Healthy · United Kingdom | 1 | Completed | AstraZeneca | Jul 18, 2017 | 42 |
| NCT05288816Healthy · United Kingdom | 1 | Completed | AstraZeneca | Jul 5, 2017 | 16 |
| NCT05288673Healthy · United Kingdom | 1 | Completed | AstraZeneca | Sep 1, 2016 | 16 |
| NCT05288660Healthy · Canada | 1 | Completed | AstraZeneca | Mar 13, 2015 | 14 |
| NCT05131204Hemoglobinuria, Paroxysmal · United States | 3 | Terminated | Regeneron Pharmaceuticals | Jul 12, 2023 | 3 |
| NCT04999020Dermatomyositis · United States, Australia, Brazil and more | 3 | Terminated | AstraZeneca | Oct 26, 2023 | 38 |
| NCT04743804Thrombotic Microangiopathies · United States, Belgium, Brazil and more | 3 | Terminated | AstraZeneca | Dec 22, 2022 | 16 |
| NCT04564339Lupus Nephritis · United States, Australia, Canada and more | 2 | Terminated | AstraZeneca | Mar 26, 2025 | 123 |
| NCT04557735Thrombotic Microangiopathies · United States, Israel, Italy and more | 3 | Completed | AstraZeneca | Nov 26, 2024 | 41 |
| NCT04543591Thrombotic Microangiopathies · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Sep 19, 2025 | 148 |
| NCT04369469Acute Lung Injury · United States, France, Japan and more | 3 | Terminated | AstraZeneca | Feb 8, 2021 | 202 |
| NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom | 4 | Completed | AstraZeneca | Dec 20, 2022 | 18 |
| NCT04248465Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more | 3 | Terminated | AstraZeneca | Oct 17, 2021 | 382 |
| NCT04201262Neuromyelitis Optica · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Mar 15, 2022 | 58 |
| NCT03920293Myasthenia Gravis · United States, Austria, Canada and more | 3 | Completed | AstraZeneca | May 11, 2021 | 175 |
| NCT03748823Hemoglobinuria, Paroxysmal · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Feb 2, 2021 | 139 |
| NCT03406507Hemoglobinuria, Paroxysmal · United States, France, Netherlands and more | 3 | Completed | AstraZeneca | Mar 25, 2020 | 13 |
| NCT03131219Atypical Hemolytic Uremic Syndrome · United States, Belgium, Germany and more | 3 | Completed | AstraZeneca | Dec 20, 2022 | 34 |
| NCT03056040Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more | 3 | Completed | AstraZeneca | Feb 21, 2022 | 202 |
| NCT02949128Atypical Hemolytic Uremic Syndrome · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Jan 24, 2023 | 58 |
| NCT02946463Hemoglobinuria, Paroxysmal · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Feb 28, 2023 | 272 |
| NCT02605993Hemoglobinuria, Paroxysmal · Canada, France, Germany and more | 2 | Completed | AstraZeneca | Feb 23, 2017 | 26 |
| NCT02598583Hemoglobinuria, Paroxysmal · Australia, Korea, Republic of | 2 | Completed | AstraZeneca | Jul 14, 2016 | 13 |
How it is read
Names in the registry
- “Ravulizumab”, 30 entries
- “ALXN1210”, 4 entries
- “ALXN1210 SC”, 1 entry
- “ALXN1210 IV”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 9 studies
- Myasthenia Gravis, 4 studies
- Thrombotic Microangiopathies, 3 studies
- Neuromyelitis Optica, 3 studies
- Atypical Hemolytic Uremic Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.